Multiple Sclerosis Clinical Trial Landscape
Data updated: May 20, 2026
856 clinical trials tracked since 2008
Multiple Sclerosis (MS) is a chronic, autoimmune disease affecting the central nervous system, disrupting communication between the brain and body. The clinical trial landscape for MS demonstrates substantial research activity, with 851 trials registered since 2008, and 182 currently active trials. These active trials span all phases of development, with a notable concentration in Phase 2 (74 active trials), followed by Phase 3 (54 active trials), Phase 1 (52 active trials), and Phase 4 (23 active trials). Industry sponsorship is led by Roche, with 19 active trials, followed by Novartis with 15. Sanofi, TG Therapeutics, Inc., and Immunic AG are also active sponsors, with 5 and 4 active trials, respectively. The distribution of active trials across phases suggests a strong focus on early-stage and mid-stage therapeutic development for MS.
182 active
/
856 total (since 2008)
55
Phase 1 Active
225 total
72
Phase 2 Active
327 total
53
Phase 3 Active
233 total
23
Phase 4 Active
172 total
Top Industry Sponsors
Sorted by active Active Done Failed
Roche 19 17 2
Novartis 15 40 14
Sanofi 5 22 2
TG Therapeutics, Inc. 5 4 0
Bristol-Myers Squibb 3 6 2
+ 10 more sponsors — see full table below
Featured Phase 3 Trials
NCT06869785 ACTIVE NOT RECRUITING
Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of a New Maintenance Dosing Regimen of Ofatumumab
Novartis Pharmaceuticals n=196
NCT06846281 RECRUITING
Efficacy and Safety of Remibrutinib After Switching From Ocrelizumab in Participants Living With Relapsing Multiple Sclerosis.
Novartis Pharmaceuticals n=360
NCT05877963 RECRUITING
Study to Evaluate Safety, Efficacy and Pharmacokinetics (PK) of a Modified Regimen of Ublituximab
TG Therapeutics, Inc. n=800
NCT07225504 RECRUITING
A Study to Evaluate the Efficacy and Safety of Remibrutinib in Secondary Progressive Multiple Sclerosis
Novartis Pharmaceuticals n=1,275
+ 228 more Phase 3 trials — see full database below
Multiple Sclerosis — Trials Started by Year (last 10 years)
2016 40
2017 44
2018 35
2019 49
2020 37
2021 56
2022 33
2023 29
2024 36
2025 41
2026 33
TheraRadar.com
Full Trial Database
Complete sponsor table, every trial across all phases, plus competitive analytics. Sortable, filterable, exportable for Pro users.
Top Sponsors (all-time)
Roche 38
Novartis 69
Sanofi 29
TG Therapeutics, Inc. 9
Bristol-Myers Squibb 11
Zenas BioPharma (USA), LLC 3
Immunic AG 3
Biogen 84
Tiziana Life Sciences LTD 3
Biocad 8
Active Trials by Phase
Phase 1 55
Phase 2 72
Phase 3 53
Phase 4 23
Enrollment Size Distribution
1-50 371
51-200 255
201-500 96
501-1k 51
1k+ 43
All Industry Sponsors
Sorted by active Active Done Failed
Roche 19 17 2
Novartis 15 40 14
Sanofi 5 22 2
TG Therapeutics, Inc. 5 4 0
Bristol-Myers Squibb 3 6 2
Zenas BioPharma (USA), LLC 3 0 0
Immunic AG 3 0 0
Biogen 2 59 23
Tiziana Life Sciences LTD 2 0 1
Biocad 1 7 0
Eli Lilly 1 2 0
Hope Biosciences Research Foundation 1 1 0
Miltenyi Biomedicine GmbH 1 0 0
Amgen 1 0 0
AstraZeneca 1 0 0
NCT06869785 ACTIVE NOT RECRUITING
Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of a New Maintenance Dosing Regimen of Ofatumumab
Novartis Pharmaceuticals n=196
NCT07220252 NOT YET RECRUITING
Study to Assess Effects of Ublituximab in Pediatric Participants With Relapsing Forms of Multiple Sclerosis
TG Therapeutics, Inc. n=240
NCT06846281 RECRUITING
Efficacy and Safety of Remibrutinib After Switching From Ocrelizumab in Participants Living With Relapsing Multiple Sclerosis.
Novartis Pharmaceuticals n=360
NCT05877963 RECRUITING
Study to Evaluate Safety, Efficacy and Pharmacokinetics (PK) of a Modified Regimen of Ublituximab
TG Therapeutics, Inc. n=800
NCT07225504 RECRUITING
A Study to Evaluate the Efficacy and Safety of Remibrutinib in Secondary Progressive Multiple Sclerosis
Novartis Pharmaceuticals n=1,275
NCT07299019 RECRUITING
A Study of Orelabrutinib in Patients With Secondary Progressive Multiple Sclerosis
Zenas BioPharma (USA), LLC n=990
NCT03650114 ACTIVE NOT RECRUITING
Long-term Safety, Tolerability and Effectiveness Study of Ofatumumab in Patients With Relapsing MS
Novartis Pharmaceuticals n=1,882
NCT05269004 ACTIVE NOT RECRUITING
A Rollover Study to Evaluate the Long-Term Safety and Efficacy of Ocrelizumab In Patients With Multiple Sclerosis
Hoffmann-La Roche n=1,300
NCT04544436 ACTIVE NOT RECRUITING
A Study to Evaluate the Efficacy, Safety and Pharmacokinetics (PK) of a Higher Dose of Ocrelizumab in Adults With Relapsing Multiple Sclerosis (RMS)
Hoffmann-La Roche n=864
NCT03523858 ACTIVE NOT RECRUITING
A Study to Evaluate Ocrelizumab Treatment in Participants With Progressive Multiple Sclerosis
Hoffmann-La Roche n=927
NCT04926818 ACTIVE NOT RECRUITING
Efficacy and Safety of Ofatumumab and Siponimod Compared to Fingolimod in Pediatric Patients With Multiple Sclerosis
Novartis Pharmaceuticals n=129
NCT06408259 RECRUITING
Study to Evaluate the Effectiveness and Safety of Ozanimod Compared to Fingolimod in Children and Adolescents With Relapsing Remitting Multiple Sclerosis
Bristol-Myers Squibb n=194
NCT06847724 RECRUITING
Comparative PK, PD, Efficacy, and Safety Assessment of the Proposed Ocrelizumab Biosimilar CYB704 and Ocrevus in Participants With Relapsing Multiple Sclerosis
Sandoz n=175
NCT07325292 RECRUITING
Non-inferiority Study of Frexalimab Subcutaneous Administration Compared to Intravenous Administration in Adult Participants With Multiple Sclerosis
Sanofi n=160
NCT06141473 ACTIVE NOT RECRUITING
Efficacy and Safety Studies of Frexalimab (SAR441344) in Adults With Relapsing Forms of Multiple Sclerosis
Sanofi n=1,655
NCT04130997 ACTIVE NOT RECRUITING
An Extension Study of Ublituximab in Participants With Relapsing Multiple Sclerosis
TG Therapeutics, Inc. n=1,100
NCT07211633 ACTIVE NOT RECRUITING
A Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety, Radiological and Clinical Effects of Subcutaneous Ublituximab in Participants With Relapsing Multiple Sclerosis (RMS)
TG Therapeutics, Inc. n=360
NCT04548999 ACTIVE NOT RECRUITING
A Study to Evaluate the Efficacy, Safety and Pharmacokinetics (PK) of a Higher Dose of Ocrelizumab in Adults With Primary Progressive Multiple Sclerosis (PPMS)
Hoffmann-La Roche n=769
NCT05156281 ACTIVE NOT RECRUITING
Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS)
Novartis Pharmaceuticals n=1,011
NCT03653273 ACTIVE NOT RECRUITING
Disease Modifying Therapies Withdrawal in Inactive Secondary Progressive Multiple Sclerosis Patients Older Than 50 Years (STOP-I-SEP)
Rennes University Hospital n=250
NCT04544449 ACTIVE NOT RECRUITING
A Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared With Ocrelizumab in Adult Participants With Primary Progressive Multiple Sclerosis
Hoffmann-La Roche n=985
NCT07483632 NOT YET RECRUITING
A Study to Learn About the Safety of Diroximel Fumarate (DRF) and Dimethyl Fumarate (DMF) and Their Effects on Relapses in Pediatric Participants With Relapsing Forms of Multiple Sclerosis (RMS)
Biogen n=185
NCT07472413 NOT YET RECRUITING
Alternate Pre-med in Anti-Cluster of Differentiation 20 (CD20) Pilot Project
University of Miami n=60
NCT04586023 ACTIVE NOT RECRUITING
Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared With Teriflunomide in Relapsing Multiple Sclerosis (RMS)
Hoffmann-La Roche n=751
NCT05147220 ACTIVE NOT RECRUITING
Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS)
Novartis Pharmaceuticals n=1,001
NCT05134441 ACTIVE NOT RECRUITING
Study to Evaluate the Efficacy, Safety, and Tolerability of IMU-838 in Patients With Relapsing Multiple Sclerosis
Immunic AG n=1,121
NCT05201638 ACTIVE NOT RECRUITING
Study to Evaluate the Efficacy, Safety and Tolerability of IMU-838 in Patients With Relapsing Multiple Sclerosis
Immunic AG n=1,100
NCT04035005 ACTIVE NOT RECRUITING
A Study to Evaluate the Efficacy and Safety of Ocrelizumab in Adults With Primary Progressive Multiple Sclerosis
Hoffmann-La Roche n=1,013
NCT06141486 ACTIVE NOT RECRUITING
Efficacy and Safety Study of Frexalimab (SAR441344) in Adults With Nonrelapsing Secondary Progressive Multiple Sclerosis
Sanofi n=943
NCT06675955 RECRUITING
An Extension Study to Assess Impact of Multiple Sclerosis (MS) on Physical Function and Provide Continued Ocrelizumab Treatment
Hoffmann-La Roche n=500
NCT04586010 ACTIVE NOT RECRUITING
A Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared With Teriflunomide in Relapsing Multiple Sclerosis (RMS)
Hoffmann-La Roche n=746
NCT06372145 ACTIVE NOT RECRUITING
A Study to Investigate Long-term Safety and Tolerability of Tolebrutinib in Participants With Multiple Sclerosis.
Sanofi n=2,500
NCT05758831 RECRUITING
RItuximab Versus Ocrelizumab in Relapsing-remitting Multiple Sclerosis.
Rennes University Hospital n=386
NCT05123703 ACTIVE NOT RECRUITING
A Study to Evaluate Safety and Efficacy of Ocrelizumab in Comparison With Fingolimod in Children and Adolescents With Relapsing-Remitting Multiple Sclerosis (RRMS)
Hoffmann-La Roche n=188
NCT05999604 RECRUITING
Impact of Annual Versus Biannual Infusions of Ocrelizumab in Patients With Active MS,After 2 Years of Initial Treatment, on Freedom From Radiological Disease Activity at Two Years: a Multicenter Randomized Controlled Non-inferiority Trial
Fondation Ophtalmologique Adolphe de Rothschild n=244
NCT07321093 RECRUITING
A Study of the Efficacy and Safety of BCD-281 in Patients With Relapsing-Remitting Multiple Sclerosis
Biocad n=292
NCT04047628 RECRUITING
Best Available Therapy Versus Autologous Hematopoietic Stem Cell Transplant for Multiple Sclerosis (BEAT-MS)
National Institute of Allergy and Infectious Diseases (NIAID) n=156
NCT07067463 RECRUITING
A Study of Orelabrutinib in Patients With Primary Progressive Multiple Sclerosis
Zenas BioPharma (USA), LLC n=705
NCT01892722 ACTIVE NOT RECRUITING
Safety and Efficacy of Fingolimod in Pediatric Patients With Multiple Sclerosis
Novartis Pharmaceuticals n=240
NCT07189325 NOT YET RECRUITING
A Prospective Randomized Non-inferiority Trial Comparing Anti-CD20 Maintenance Versus De-Escalation Strategy In Relapsing-Remitting Multiple Sclerosis
University Hospital, Montpellier n=250
NCT03958877 ACTIVE NOT RECRUITING
A Study to Evaluate the Safety, Tolerability, and Efficacy of BIIB017 (Peginterferon Beta-1a) in Pediatric Participants for the Treatment of Relapsing-Remitting Multiple Sclerosis
Biogen n=152
NCT04695080 ACTIVE NOT RECRUITING
ChariotMS - Cladribine to Halt Deterioration in People With Advanced Multiple Sclerosis
Queen Mary University of London n=204
NCT04688788 ACTIVE NOT RECRUITING
Non-inferiority Study of Ocrelizumab and Rituximab in Active Multiple Sclerosis
Rigshospitalet, Denmark n=600
NCT04578639 ACTIVE NOT RECRUITING
Ocrelizumab VErsus Rituximab Off-Label at the Onset of Relapsing MS Disease
Haukeland University Hospital n=214
NCT03477500 ACTIVE NOT RECRUITING
Randomized Autologous heMatopoietic Stem Cell Transplantation Versus Alemtuzumab, Cladribine or Ocrelizumab for RRMS (RAM-MS)
Haukeland University Hospital n=100
NCT06663189 NOT YET RECRUITING
Disease Modifying Therapies Withdrawal in Inactive Relapsing-remitting Multiple Sclerosis Patients Aged 55 and Over (TWINS : Therapies Withdrawal IN Relapsing Multiple Sclerosis)
University Hospital, Strasbourg, France n=200
NCT05906992 RECRUITING
A Study to Compare Efficacy, Pharmacokinetics, Pharmacodynamics and Safety of CT-P53 and Ocrevus in Patients With Relapsing-remitting Multiple Sclerosis
Celltrion n=512
NCT05210621 ACTIVE NOT RECRUITING
LONG-TERM EFFECTIVENESS AND SAFETY EVALUATION OF OCRELIZUMAB
Centre Hospitalier Universitaire de Nice n=72
NCT05961644 RECRUITING
Cladribine vs Placebo for Non-active Progressive Multiple Sclerosis (CLASP-MS).
Institute of Psychiatry and Neurology, Warsaw n=188
NCT05834855 RECRUITING
Non-inferiority Study of Rituximab Compared to Ocrelizumab in Relapsing MS
Amsterdam UMC, location VUmc n=200
NCT04815967 ACTIVE NOT RECRUITING
Efficacy and Safety Study of MYOBLOC® in the Treatment of Adult Upper Limb Spasticity
Supernus Pharmaceuticals, Inc. n=272
NCT01149525 COMPLETED
Efficacy of L-carnitine Versus Placebo in the Treatment of Fatigue in Multiple Sclerosis
University Hospital, Bordeaux n=59
NCT05338450 TERMINATED
Clemastine Fumarate as Remyelinating Treatment in Internuclear Ophthalmoparesis and Multiple Sclerosis
Amsterdam UMC, location VUmc n=47
NCT05441488 SUSPENDED
Masitinib in the Treatment of Patients With Primary Progressive or Non-active Secondary Progressive Multiple Sclerosis
AB Science n=800
NCT04353492 COMPLETED
An Open-label Study Evaluating Ofatumumab Treatment Effectiveness and PROs in Subjects With RMS Transitioning From Fumarate-based RMS Approved Therapies or Fingolimod to Ofatumumab
Novartis Pharmaceuticals n=562
NCT04788615 COMPLETED
Open Label Randomized Multicenter to Assess Efficacy & Tolerability of Ofatumumab 20mg vs. First Line DMT in RMS
Novartis Pharmaceuticals n=185
NCT04510220 COMPLETED
9-month Study to Assess the Efficacy of Ofatumumab on Microglia in Patients With Relapsing Forms of Multiple Sclerosis
Brigham and Women's Hospital n=10
NCT04486716 COMPLETED
A Single Arm Study Evaluating the Efficacy, Safety and Tolerability of Ofatumumab in Patients With Relapsing Multiple Sclerosis
Novartis Pharmaceuticals n=111
NCT04458051 COMPLETED
Primary Progressive Multiple Sclerosis (PPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168) (PERSEUS)
Sanofi n=767
NCT03368664 TERMINATED
A Study to Evaluate Efficacy, Safety, and Tolerability of Alemtuzumab in Pediatric Patients With RRMS With Disease Activity on Prior DMT
Genzyme, a Sanofi Company n=16
NCT05265728 TERMINATED
A Study to Evaluate Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Multiple Doses of Natalizumab (BG00002) Administered Subcutaneously to Japanese Participants With Relapsing-Remitting Multiple Sclerosis
Biogen n=21
NCT03599245 COMPLETED
This is an Extension Study of the Roche P-trials to Investigate Safety and Effectiveness of Ocrelizumab in Participants With Multiple Sclerosis (MS)
Hoffmann-La Roche n=1,055
NCT05083923 COMPLETED
A Study of Diroximel Fumarate (DRF) in Adult Participants From the Asia-Pacific Region With Relapsing Forms of Multiple Sclerosis (RMS)
Biogen n=136
NCT05232825 COMPLETED
A Phase III, Non-Inferiority, Randomized, Open-Label, Parallel Group, Multicenter Study To Investigate The Pharmacokinetics, Pharmacodynamics, Safety And Radiological And Clinical Effects Of Subcutaneous Ocrelizumab Versus Intravenous Ocrelizumab In Patients With Multiple Sclerosis
Hoffmann-La Roche n=236
NCT02283853 COMPLETED
Phase 3 Efficacy and Safety Study of BG00012 in Pediatric Participants With Relapsing-Remitting Multiple Sclerosis (RRMS)
Biogen n=156
NCT04411641 COMPLETED
Nonrelapsing Secondary Progressive Multiple Sclerosis (NRSPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168) (HERCULES)
Sanofi n=1,131
NCT04410978 COMPLETED
Relapsing Forms of Multiple Sclerosis (RMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168) (GEMINI 1)
Sanofi n=974
NCT04410991 COMPLETED
Relapsing Forms of Multiple Sclerosis (RMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168) (GEMINI 2)
Sanofi n=899
NCT03232073 COMPLETED
Long-term Extension to Study AC-058B301 to Investigate Safety, Tolerability and Disease Control of Ponesimod 20 mg in Patients With Relapsing Multiple Sclerosis
Actelion n=877
NCT04338022 TERMINATED
Study of Evobrutinib in Participants With RMS (evolutionRMS 1)
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany n=1,124
NCT04140305 TERMINATED
Study Describing Cognitive Processing Speed Changes in Relapsing Multiple Sclerosis Subjects Treated With Ozanimod (RPC-1063)
Celgene n=188
NCT06987851 COMPLETED
An Extension Clinical Study of the Efficacy and Safety of BCD-132 in Patients With Multiple Sclerosis Who Previously Received Therapy in Clinical Studies of JSC BIOCAD
Biocad n=44
NCT04925557 TERMINATED
Study to Assess the Efficacy of Mayzent on Microglia in Secondary Progressive Multiple Sclerosis
State University of New York at Buffalo n=8
NCT02425644 COMPLETED
Oral Ponesimod Versus Teriflunomide In Relapsing MUltiple Sclerosis
Actelion n=1,133
NCT04338061 TERMINATED
Study of Evobrutinib in Participants With RMS (evolutionRMS 2)
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany n=1,166
NCT05028634 COMPLETED
Safety Study to Evaluate Immune Response of Vaccines in Participants With Relapsing Forms of Multiple Sclerosis Who Receive Ozanimod Compared to Non-Pegylated Interferon (IFN)-β or No Disease Modifying Therapy
Celgene n=63
NCT02201108 COMPLETED
Efficacy, Safety and Pharmacokinetics of Teriflunomide in Pediatric Patients With Relapsing Forms of Multiple Sclerosis
Genzyme, a Sanofi Company n=166
NCT03085810 TERMINATED
Study to Evaluate the Effectiveness and Safety of Ocrelizumab in Participants With Early Stage Relapsing Remitting Multiple Sclerosis (RRMS)
Hoffmann-La Roche n=1,225
NCT04121403 COMPLETED
Norwegian Study of Oral Cladribine and Rituximab in Multiple Sclerosis (NOR-MS)
Oslo University Hospital n=267
NCT04984278 TERMINATED
Evaluation of the Effect of Nabiximols Oromucosal Spray on Clinical Measures of Spasticity in Participants With Multiple Sclerosis
Jazz Pharmaceuticals n=56
NCT05385744 COMPLETED
An International, Multicenter, Randomized, Double-Blind, Double-Masked Study of the Efficacy and Safety of BCD-132 (JSC BIOCAD, Russia) Using an Active Reference Drug (Teriflunomide) for the Treatment of Patients With Multiple Sclerosis
Biocad n=336
NCT03283397 TERMINATED
A Phase IIIb, Multicenter, International Study to Evaluate the Efficacy, Safety and Tolerability of EK-12 in Patients With RRMS
Bosnalijek D.D n=301
NCT03623243 COMPLETED
Safety and Tolerability of Conversion From Oral, Injectable, or Infusion Disease Modifying Therapies to Dose-titrated Oral Siponimod (Mayzent) in Advancing RMS Patients
Novartis Pharmaceuticals n=185
NCT03689972 COMPLETED
A Study to Evaluate Efficacy, Safety, and Tolerability of EID of Natalizumab (BG00002) in Participants With RRMS Switching From Treatment With Natalizumab SID in Relation to Continued SID Treatment- Followed by Extension Study Comprising SC and IV Natalizumab Administration
Biogen n=585
NCT01665144 COMPLETED
Exploring the Efficacy and Safety of Siponimod in Patients With Secondary Progressive Multiple Sclerosis (EXPAND)
Novartis Pharmaceuticals n=1,651
NCT02688985 COMPLETED
Study to Explore the Mechanism of Action of Ocrelizumab and B-Cell Biology in Participants With Relapsing Multiple Sclerosis (RMS) or Primary Progressive Multiple Sclerosis (PPMS)
Genentech, Inc. n=131
NCT04203498 TERMINATED
Safety and Effectiveness of Nabiximols Oromucosal Spray as Add-on Therapy in Participants With Spasticity Due to Multiple Sclerosis
Jazz Pharmaceuticals n=139
NCT02545868 COMPLETED
A Study to Evaluate the Effects of Ocrelizumab on Immune Responses In Participants With Relapsing Forms of Multiple Sclerosis
Hoffmann-La Roche n=102
NCT01412333 COMPLETED
A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Participants With Relapsing Multiple Sclerosis
Hoffmann-La Roche n=835
NCT04175834 COMPLETED
Comparing Risk and Severity of IRRs in Patients Premedicated With Cetirizine vs. Diphenhydramine Prior to Ocrelizumab
Providence Health & Services n=19
NCT01247324 COMPLETED
A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Participants With Relapsing Multiple Sclerosis
Hoffmann-La Roche n=821
NCT02576717 COMPLETED
A Multi-Site, Open-Label Extension Trial of Oral RPC1063 in Relapsing Multiple Sclerosis
Celgene n=2,494
NCT01817166 COMPLETED
Efficacy of Cholecalciferol (Vitamin D3) for Delaying the Diagnosis of MS After a Clinically Isolated Syndrome
Centre Hospitalier Universitaire de Nīmes n=316
NCT01194570 COMPLETED
A Study of Ocrelizumab in Participants With Primary Progressive Multiple Sclerosis
Hoffmann-La Roche n=735
NCT04626921 COMPLETED
A Multi-Center, Open-Label Long-Term Extension Study of CNM-Au8 In Patients With Stable Relapsing Multiple Sclerosis
Clene Nanomedicine n=55
NCT04121221 COMPLETED
A Study to Asses Efficacy, Safety and Tolerability of Monthly Long-acting IM Injection of GA Depot in Subjects With RMS
Mapi Pharma Ltd. n=1,016
NCT04657666 COMPLETED
Trial to Evaluate the Effect of Nabiximols Oromucosal Spray on Clinical Measures of Spasticity in Participants With Multiple Sclerosis
Jazz Pharmaceuticals n=68
NCT04115488 COMPLETED
Efficacy and Safety of the Biosimilar Natalizumab PB006 in Comparison to Tysabri®
Polpharma Biologics S.A. n=265
NCT03870763 TERMINATED
Study to Evaluate the Efficacy and Safety of Dimethyl Fumarate (Tecfidera) and Peginterferon Beta-1a (Plegridy) for the Treatment of Relapsing-Remitting Multiple Sclerosis in Pediatric Participants
Biogen n=11
NCT05859802 COMPLETED
Effects of Physical Therapy and Dalfampridine on Functional Mobility in Non Ambulatory Persons With Multiple Sclerosis
D'Youville College n=35
NCT00681538 COMPLETED
A Study of the Safety and Effectiveness of Sativex®, for the Relief of Symptoms of Spasticity in Subjects, From Phase B, With Multiple Sclerosis (MS)
Jazz Pharmaceuticals n=572
NCT02937285 COMPLETED
National Multicenter, Controlled, Single-blind Study With Two Parallel Groups Evaluating the Safety and Efficacy of Sequential Treatment With Mitoxantrone and Interferon Versus Interferon Alone in Patients With Strong Risk of Progression in the Initial Phase of Multiple Sclerosis
Rennes University Hospital n=35
NCT02587195 COMPLETED
A Study to Evaluate the Safety of Long Term Treatment With Teriflunomide 14 mg Once Daily in Patients With a First Clinical Episode Suggestive of Multiple Sclerosis in a Long-term Extension Period
Centre Hospitalier Universitaire de Nice n=5
NCT03122652 COMPLETED
Randomized, Double-blinded Study of Treatment:Teriflunomide, in Radiologically Isolated Syndrome
Centre Hospitalier Universitaire de Nice n=125
NCT02727907 COMPLETED
Study of Efficacy and Safety of Drugs BCD-033 and Rebif for Treatment of Patients With Multiple Sclerosis
Biocad n=163
NCT05242133 COMPLETED
Efficacy and Safety of Peginterferon Beta-1a (CinnaGen) in Participants With Relapsing Remitting Multiple Sclerosis
Cinnagen n=168
NCT04966338 COMPLETED
Efficacy and Safety of Xacrel® (Ocrelizumab) in Participants With Relapsing Remitting Multiple Sclerosis
Cinnagen n=170
NCT01490502 COMPLETED
Vitamin D Supplementation in Multiple Sclerosis
Johns Hopkins University n=172
NCT03774407 COMPLETED
Vaginal Estriol in Multiple Sclerosis
Texas Tech University Health Sciences Center n=21
NCT03319732 COMPLETED
A Study to Evaluate the Long-term Safety of Arbaclofen Extended-Release Tablets for Patients With Spasticity Due to MS
RVL Pharmaceuticals, Inc. n=323
NCT04595045 COMPLETED
Botulinum Toxin in Patients With Spastic Lower Limb Paresis Associated With Multiple Sclerosis
Aránzazu Vázquez Doce n=84
NCT02634307 COMPLETED
A Study of ALKS 8700 in Adults With Relapsing Remitting Multiple Sclerosis (MS) EVOLVE-MS-1
Biogen n=1,057
NCT03290131 COMPLETED
A Study to Investigate the Safety and Effectiveness of Arbaclofen Extended-Release Tablets for Patients With MS
RVL Pharmaceuticals, Inc. n=536
NCT02869425 WITHDRAWN
To Assess Effects of Arbaclofen ER Tablets Compared With Placebo on Sperm Parameters in Male Subjects With MS
RVL Pharmaceuticals, Inc.
NCT01844232 COMPLETED
One Year, Open Label, Dose Escalation Long-term Safety Study in Multiple Sclerosis (MS) Subjects With Spasticity
RVL Pharmaceuticals, Inc. n=150
NCT01743651 COMPLETED
Efficacy Study of Arbaclofen to Treat Spasticity in Multiple Sclerosis
RVL Pharmaceuticals, Inc. n=353
NCT00605215 COMPLETED
BRAVO Study: Laquinimod Double-blind Placebo-controlled Study in Participants With Relapsing-Remitting Multiple Sclerosis (RRMS) With a Rater Blinded Reference Arm of Interferon β-1a (Avonex®)
Teva Branded Pharmaceutical Products R&D, Inc. n=1,331
NCT02861014 COMPLETED
A Study of Ocrelizumab in Participants With Relapsing Remitting Multiple Sclerosis (RRMS) Who Have Had a Suboptimal Response to an Adequate Course of Disease-Modifying Treatment (DMT)
Hoffmann-La Roche n=681
NCT03567057 COMPLETED
A Safety and Efficacy Study of ADS-5102 in Patients With Multiple Sclerosis and Walking Impairment
Adamas Pharmaceuticals, Inc. n=424
NCT03436199 COMPLETED
Safety and Efficacy of ADS-5102 in Multiple Sclerosis Patients With Walking Impairment
Adamas Pharmaceuticals, Inc. n=558
NCT01047319 TERMINATED
A Study to Evaluate the Long-term Safety, Tolerability and Effect of Daily Oral Laquinimod 0.6 mg on Disease Course in Subjects With Relapsing Multiple Sclerosis
Teva Branded Pharmaceutical Products R&D, Inc. n=1,047
NCT01067521 COMPLETED
A Study in Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS) to Assess the Efficacy, Safety and Tolerability of Glatiramer Acetate (GA) Injection 40 mg Administered Three Times a Week Compared to Placebo
Teva Branded Pharmaceutical Products R&D, Inc. n=1,404
NCT00988052 TERMINATED
A Study To Evaluate the Long-Term Safety, Tolerability and Effect on Disease Course
Teva Branded Pharmaceutical Products R&D, Inc. n=839
NCT03277248 COMPLETED
Study to Assess the Efficacy and Safety of Ublituximab in Participants With Relapsing Forms of Multiple Sclerosis (RMS)
TG Therapeutics, Inc. n=545
NCT03277261 COMPLETED
Study to Assess the Efficacy and Safety of Ublituximab in Participants With Relapsing Forms of Multiple Sclerosis (RMS) ( ULTIMATE 1 )
TG Therapeutics, Inc. n=549
NCT01975298 WITHDRAWN
A Study to Evaluate 2 Doses Of Oral Administration Of Laquinimod Compared to Interferon ß-1a Administered by Injection in Participants With Relapsing Remitting Multiple Sclerosis (RRMS)
Teva Branded Pharmaceutical Products R&D, Inc.
NCT01707992 COMPLETED
The Efficacy, Safety, and Tolerability of Laquinimod in Participants With Relapsing Remitting Multiple Sclerosis (RRMS)
Teva Branded Pharmaceutical Products R&D, Inc. n=2,199
NCT02746744 COMPLETED
RItuximab Versus FUmarate in Newly Diagnosed Multiple Sclerosis.
Anders Svenningsson n=200
NCT02792218 COMPLETED
Efficacy and Safety of Ofatumumab Compared to Teriflunomide in Patients With Relapsing Multiple Sclerosis
Novartis Pharmaceuticals n=930
NCT02753088 COMPLETED
Efficacy and Safety of BCD-063 and Copaxone-Teva in Patients With Relapsing-Remitting Multiple Sclerosis
Biocad n=158
NCT02744222 COMPLETED
Comparative Clinical Trial to Evaluate Efficacy, Safety and Tolerance of BCD-054 and Avonex® for Treatment of Patients With Remitting-relapsing Multiple Sclerosis
Biocad n=399
NCT04032158 TERMINATED
Study of Evobrutinib in Participants With Relapsing Multiple Sclerosis (RMS)
EMD Serono Research & Development Institute, Inc. n=3
NCT04032171 TERMINATED
Study of Evobrutinib in Participants With RMS
EMD Serono Research & Development Institute, Inc. n=1
NCT01647880 TERMINATED
MOdification of VIsual Outcomes After Optic Neuritis in CIS or MS by Gilenya (MOVING Study)
Charite University, Berlin, Germany n=15
NCT02980042 COMPLETED
Safety of Switching From Rituximab to Ocrelizumab in MS Patients
University of Colorado, Denver n=200
NCT02907177 TERMINATED
Clinical Study to Compare the Efficacy and Safety of Ponesimod to Placebo in Subjects With Active Relapsing Multiple Sclerosis Who Are Treated With Dimethyl Fumarate (Tecfidera®)
Actelion n=136
NCT01201356 COMPLETED
Long-term Safety and Tolerability of 0.5 mg Fingolimod in Patients With Relapsing Forms of Multiple Sclerosis
Novartis Pharmaceuticals n=4,125
NCT00725985 COMPLETED
Oral Cladribine in Early Multiple Sclerosis (MS)
EMD Serono Research & Development Institute, Inc. n=617
NCT01359566 COMPLETED
Efficacy and Safety of Arbaclofen Placarbil in Subjects With Spasticity Due to Multiple Sclerosis
XenoPort, Inc. n=228
NCT01628393 COMPLETED
Efficacy and Safety Study of Ozanimod (RPC1063) in Relapsing Multiple Sclerosis Patients
Celgene n=258
NCT02047734 COMPLETED
Efficacy and Safety Study of Ozanimod in Relapsing Multiple Sclerosis
Celgene n=1,320
NCT03342638 TERMINATED
Maximizing Outcome of Multiple Sclerosis Transplantation
Northwestern University n=66
NCT00835770 COMPLETED
BG00012 Monotherapy Safety and Efficacy Extension Study in Multiple Sclerosis (MS)
Biogen n=1,736
NCT00641537 COMPLETED
CLARITY Extension Study
EMD Serono Research & Development Institute, Inc. n=867
NCT02294058 COMPLETED
Study of Ozanimod (RPC1063) in Relapsing Multiple Sclerosis (MS)
Celgene n=1,346
NCT02936037 TERMINATED
Effect of MD1003 in Progressive Multiple Sclerosis (SPI2)
MedDay Pharmaceuticals SA n=642
NCT03185065 COMPLETED
Treatment of Fatigue With Methylphenidate, Modafinil and Amantadine in Multiple Sclerosis
Johns Hopkins University n=141
NCT02006160 COMPLETED
Effects of Dalfampridine on Cognition in Multiple Sclerosis
State University of New York at Buffalo n=61
NCT03093324 COMPLETED
A Tolerability Study of ALKS 8700 in Subjects With Relapsing Remitting Multiple Sclerosis (RRMS) EVOLVE-MS-2
Biogen n=506
NCT03606460 COMPLETED
A Study to Evaluate the Safety of Administering Ocrelizumab Per a Shorter Infusion Protocol in Participants With Primary Progressive Multiple Sclerosis (PPMS) and Relapsing Multiple Sclerosis (RMS)
Genentech, Inc. n=141
NCT02637856 COMPLETED
A Study of Ocrelizumab in Participants With Relapsing Remitting Multiple Sclerosis (RRMS) Who Have Had a Suboptimal Response to an Adequate Course of Disease-Modifying Treatment (DMT)
Genentech, Inc. n=608
NCT01433497 COMPLETED
Efficacy and Safety of Masitinib in the Treatment of Progressive Multiple Sclerosis
AB Science n=656
NCT02290444 COMPLETED
Effects of Acthar on Recovery From Cognitive Relapses in MS
State University of New York at Buffalo n=64
NCT01337986 COMPLETED
Ampyra for Optic Neuritis in Multiple Sclerosis
Washington University School of Medicine n=53
NCT01797965 TERMINATED
Long-Term Extension Study in Participants With Multiple Sclerosis Who Have Completed Study 205MS301 (NCT01064401) to Evaluate the Safety and Efficacy of BIIB019
Biogen n=1,501
NCT02555215 COMPLETED
Extension Study of BG00012 in Pediatric Subjects With Relapsing Remitting Multiple Sclerosis (RRMS)
Biogen n=20
NCT02881567 TERMINATED
Efficacy and Safety of Daclizumab in Participants With RRMS Switching From Natalizumab
Biogen n=41
NCT02315872 COMPLETED
ACTH for Fatigue in Multiple Sclerosis Patients
Providence Health & Services n=8
NCT02525874 COMPLETED
Effect of BG00012 on Lymphocyte Subsets and Immunoglobulins in Subjects With Relapsing Remitting Multiple Sclerosis (RRMS).
Biogen n=218
NCT01633112 TERMINATED
MS Study Evaluating Safety and Efficacy of Two Doses of Fingolimod Versus Copaxone
Novartis Pharmaceuticals n=1,064
NCT03315923 COMPLETED
Comparison of Clinical Effects of Rituximab and Glatiramer Acetate in Secondary Progressive Multiple Sclerosis Patients
Isfahan University of Medical Sciences n=84
NCT02939079 COMPLETED
Evaluating of the Effect of Fingolimod With Fish Oil on Relapsing-Remitting Multiple Sclerosis Patients
Isfahan University of Medical Sciences n=50
NCT00965497 COMPLETED
Escitalopram (Lexapro) for Depression MS or ALS
University of South Carolina n=13
NCT01600716 COMPLETED
Safety and Efficacy Study of OnabotulinumtoxinA for the Treatment of Urinary Incontinence Due to Neurogenic Detrusor Overactivity (NDO) in Non-Catheterizing Patients With Multiple Sclerosis (MS)
Allergan n=144
NCT01838668 COMPLETED
An Efficacy and Safety Study of BG00012 (Dimethyl Fumarate) in Asian Subjects With Relapsing Remitting Multiple Sclerosis (RRMS)
Biogen n=225
NCT01307332 COMPLETED
Advanced MRI Measures of Repair in Alemtuzumab Treated Patients
University of British Columbia n=27
NCT03172741 WITHDRAWN
The Effects of Different Medical Marijuana Strains on Motor and Cognitive Function in People With Multiple Sclerosis
Colorado State University
NCT01896700 COMPLETED
Methylphenidate to Improve Balance and Walking in MS
Oregon Health and Science University n=24
NCT01442233 COMPLETED
Plasma Exchanges in Multiple Sclerosis (MS) Relapses
University Hospital, Bordeaux n=38
NCT01416181 TERMINATED
A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Participants With Secondary Progressive Multiple Sclerosis
Biogen n=889
NCT00731692 TERMINATED
This Was an Open-label, Single-arm Extension Study (CFTY720D2306E1) to a Double-blind, Randomized Multicenter, Placebo-controlled, Parallel-group Core Study (CFTY720D2306) in PPMS.
Novartis Pharmaceuticals n=970
NCT00930553 COMPLETED
An Extension Protocol for Multiple Sclerosis Patients Who Participated in Genzyme-Sponsored Studies of Alemtuzumab
Genzyme, a Sanofi Company n=1,314
NCT02579681 COMPLETED
Study Assessing Cognition in Relapsing Remitting Multiple Sclerosis (RRMS) Patients Treated With BG00012
Biogen n=221
NCT02430532 TERMINATED
BG00012 and Delay of Disability Progression in Secondary Progressive Multiple Sclerosis
Biogen n=58
NCT01941004 WITHDRAWN
Safety and Efficacy of Fingolimod in MS Patients in China
Novartis Pharmaceuticals
NCT02219932 COMPLETED
Efficacy and Safety Study of Prolonged-Release Fampridine in Participants With Multiple Sclerosis
Biogen n=646
NCT01917019 COMPLETED
A Safety and Efficacy Study of Oral Prolonged-Release Fampridine (BIIB041) in Japanese Participants With Multiple Sclerosis
Biogen n=101
NCT01462318 COMPLETED
An Open-Label Immunogenicity and Pharmacokinetics Study of Daclizumab High Yield Process Prefilled Syringe in Relapsing Remitting Multiple Sclerosis
Biogen n=133
NCT00947752 COMPLETED
Safety of New Formulation of Glatiramer Acetate
Teva Branded Pharmaceutical Products R&D, Inc. n=147
NCT00622700 COMPLETED
Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis
Sanofi n=618
NCT00813709 COMPLETED
Long-term Follow-Up of Patients Who Participated in Study 27025 (REFLEX)
Merck KGaA, Darmstadt, Germany n=402
NCT01127750 COMPLETED
Tolerability and Safety and Health Outcomes in Relapsing Multiple Sclerosis (MS) Patients
Novartis n=2,417
NCT00856518 COMPLETED
Expiratory Muscle Training for Persons With Neurodegenerative Disease
VA Office of Research and Development n=42
NCT01188811 COMPLETED
Lipoic Acid for Secondary Progressive Multiple Sclerosis (MS)
VA Office of Research and Development n=54
NCT01939002 COMPLETED
Characterize Flu-like Symptoms in Relapsing Multiple Sclerosis Patients Transitioning From Non-Pegylated Interferon Beta (IFN-β) Therapies to Peginterferon Beta-1a (BIIB017)
Biogen n=251
NCT01064401 COMPLETED
Efficacy and Safety of BIIB019 (Daclizumab High Yield Process) Versus Interferon β 1a in Participants With Relapsing-Remitting Multiple Sclerosis
Biogen n=1,841
NCT00751881 COMPLETED
An Efficacy Study of Teriflunomide in Participants With Relapsing Multiple Sclerosis
Sanofi n=1,169
NCT00883337 COMPLETED
A Study Comparing the Effectiveness and Safety of Teriflunomide and Interferon Beta-1a in Patients With Relapsing Multiple Sclerosis
Sanofi n=324
NCT02428218 WITHDRAWN
Placebo-Controlled Study of the Efficacy and Safety of BG00012 in Pediatric Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS)
Biogen
NCT00947895 TERMINATED
Efficacy Study of Adrenocorticotropin Hormone to Treat Multiple Sclerosis (MS) Relapses After Sub-responding to an Initial 3 Day Course of Intravenous (IV) Methylprednisolone
Neurologique Foundation, Inc. n=30
NCT01874145 COMPLETED
Safety and Tolerability of Glatiramer Acetate
Teva Branded Pharmaceutical Products R&D, Inc. n=209
NCT01667484 COMPLETED
Adderall XR and Processing Speed in Multiple Sclerosis (MS)
London Health Sciences Centre n=70
NCT01018485 COMPLETED
The Efficacy of Botulinum Toxin in Disabling Multiple Sclerosis (MS) Tremor
Melbourne Health n=30
NCT01497262 COMPLETED
Safety and Tolerability of Fingolimod in Patients With Relapsing-remitting Multiple Sclerosis
Novartis Pharmaceuticals n=162
NCT01863888 COMPLETED
Effect of Teriflunomide on Immune Cell Subsets in the Blood of Patients With Multiple Sclerosis
Sanofi n=70
NCT01440101 COMPLETED
Natalizumab (BG00002, Tysabri) Study in Japanese Participants With Relapsing-Remitting Multiple Sclerosis (RRMS)
Biogen n=106
NCT00906399 COMPLETED
Efficacy and Safety Study of Peginterferon Beta-1a in Participants With Relapsing Multiple Sclerosis
Biogen n=1,516
NCT01337427 WITHDRAWN
Using Optical Coherence Tomography (OCT) to Evaluate the Efficacy and Safety of PEGylated Interferon Beta-1a (BIIB017) in Patients With Relapsing Multiple Sclerosis
Johns Hopkins University
NCT01058005 TERMINATED
Study Evaluating Rebif, Copaxone, and Tysabri for Active Multiple Sclerosis
Biogen n=84
NCT01499667 TERMINATED
Disease Control and Safety in Patients With Relapsing Remitting Multiple Sclerosis (RRMS) Switching From Natalizumab to Fingolimod
Novartis Pharmaceuticals n=142
NCT01235221 COMPLETED
Open Label Extension Study to Evaluate the Safety and Tolerability of Oral Fampridine-Sustained Release (SR) in Canadian Participants With Multiple Sclerosis Who Participated in Acorda Extension Trials.
Biogen n=38
NCT01252355 TERMINATED
Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta
Sanofi n=534
NCT00828204 COMPLETED
Evaluate the Safe and Effective Use of the Avonex® Single-Use Autoinjector in Multiple Sclerosis Subjects
Biogen n=95
NCT00784836 TERMINATED
Immunogenicity and Safety of Subcutaneously-administered Avonex (Interferon Beta-1a) in Multiple Sclerosis (MS) Patients
Biogen n=3
NCT01578785 TERMINATED
An Efficacy, Safety and Tolerability Study of Glatiramer Acetate (GA) 20 mg/0.5 ml New Formulation Administered Daily by Subcutaneous (SC) Injection in Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS)
Teva Branded Pharmaceutical Products R&D, Inc. n=178
NCT00429442 WITHDRAWN
Simvastatin as an add-on Treatment to Copaxone for the Treatment of Relapsing Multiple Sclerosis
Anna Tsakiri
NCT01103583 TERMINATED
Hydroxyurea in Primary Progressive Multiple Sclerosis
S. Andrea Hospital n=33
NCT01538225 COMPLETED
Neurophysiological Study of Sativex in Multiple Sclerosis (MS) Spasticity
Almirall, S.A. n=45
NCT00735007 COMPLETED
12-week Study to Evaluate RebiSmart™ Suitability for Self Injection in Relapsing Multiple Sclerosis.
EMD Serono n=106
NCT01167426 COMPLETED
Evaluation of Two Glatiramer Acetate (GA) Formulations in Relapsing-Remitting Multiple Sclerosis (RRMS) Patients
Teva Neuroscience, Inc. n=148
NCT00981084 COMPLETED
Impact of Armodafinil on Neurocognition and Cognitive Fatigue in Multiple Sclerosis (MS)
University of Missouri, Kansas City n=33
NCT01181115 COMPLETED
Avonex Safety and Tolerability in Chinese Subjects With Relapsing Multiple Sclerosis (MS)
Biogen n=60
NCT01328379 COMPLETED
Study of Fampridine-ER Tablets in Patients With Multiple Sclerosis
Acorda Therapeutics n=430
NCT01036165 COMPLETED
A Multicenter, Open-label, RebiSmart™ Autoinjector Ease of Use Study
EMD Serono n=103
NCT00958009 COMPLETED
The Multicenter, Open-label, Single-use Autoinjector Convenience Study
EMD Serono n=109
NCT00662649 COMPLETED
Long-term Efficacy and Safety of Fingolimod (FTY720) in Patients With Relapsing-remitting Multiple Sclerosis
Novartis n=920
NCT01199861 COMPLETED
Effect of Treatment With Fingolimod on the Immune Response Following Seasonal Flu Vaccination and Tetanus Booster Injection in Patients With Relapsing Multiple Sclerosis (MS)
Novartis n=138
NCT01432704 COMPLETED
Colecalciferol as an Add-on Treatment to Subcutaneously-Administered Interferon-beta-1b for Treatment of Multiple Sclerosis (MS)
University of Turku n=70
NCT07595081 COMPLETED
Propionic Acid for Multiple Sclerosis: Safety and Benefits
Salzburger Landeskliniken n=22
Data: ClinicalTrials.gov · Trials registered 2008 onwards · Industry sponsors only